EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY 4.0

Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery

Satoru Morimoto, Shinichi Takahashi, Daisuke Ito, Yugaku Daté, Kensuke Okada, Chris Kato, Shiho Nakamura, Fumiko Ozawa, Chai Muh Chyi, Ayumi Nishiyama, Naoki Suzuki, Koki Fujimori und 13 weitere

Cell Stem Cell · 2023-06 · 30 (6) · 766-780.e9

DOI: 10.1016/j.stem.2023.04.017 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cell Stem Cell, 2023-06. Verfasst von Satoru Morimoto und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Neurology, Keio University School of Medicine, Tok…. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Japan, JSPS, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisInduced Pluripotent Stem CellsHumansIndolesMotor Neurons

Stichwörter der Autor:innen

ALSPRO-ACT registry dataamyotrophic lateral sclerosischolesterol synthesisdopamine D2 receptor agonistiPSC drug discoveryphase 1/2a trialreverse translational researchropinirole hydrochloridetranslational research

Substanzen

Indolesropinirole

Autor:innen und Institutionen

  • Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Neurology, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Neurology, Keio University School of Medicine, Tokyo 160-8582, Japan; Department of Neurology and Stroke, Saitama Medica…
  • Department of Neurology, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan; Keio University Global Research Institute, Tokyo 108-8345, Japan.
  • Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan.

Förderung

  • GlaxoSmithKline Japan
  • JSPS
  • Japan Society for the Promotion of Science
  • Ministry of Education, Culture, Sports, Science and Technology
  • Ministry of Health, Labour and Welfare
  • Japan Agency for Medical Research and Development
  • National Center of Neurology and Psychiatry
  • Uehara Memorial Foundation

Zitieren

APA

Morimoto, S., Takahashi, S., Ito, D., Daté, Y., Okada, K., Kato, C., Nakamura, S., Ozawa, F., Chyi, C. M., Nishiyama, A., Suzuki, N., Fujimori, K., Kondo, T., Takao, M., Hirai, M., Kabe, Y., Suematsu, M., Jinzaki, M., Aoki, M., …, & Okano, H. (2023). Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery. Cell Stem Cell, 30(6), 766-780.e9. https://doi.org/10.1016/j.stem.2023.04.017

Vancouver

Morimoto S, Takahashi S, Ito D, Daté Y, Okada K, Kato C, et al. Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery. Cell Stem Cell. 2023;30(6):766-780.e9. doi:10.1016/j.stem.2023.04.017

BibTeX
@article{Morimoto2023,
  author = {Morimoto, Satoru and Takahashi, Shinichi and Ito, Daisuke and Daté, Yugaku and Okada, Kensuke and Kato, Chris and Nakamura, Shiho and Ozawa, Fumiko and Chyi, Chai Muh and Nishiyama, Ayumi and Suzuki, Naoki and Fujimori, Koki and Kondo, Tosho and Takao, Masaki and Hirai, Miwa and Kabe, Yasuaki and Suematsu, Makoto and Jinzaki, Masahiro and Aoki, Masashi and Fujiki, Yuto and Sato, Yasunori and Suzuki, Norihiro and Nakahara, Jin and Pooled Resource Open-Access ALS Clinical Trials Consortium, Pooled Resource Open-Access ALS Clinical Trials Consortium and Okano, Hideyuki},
  title = {Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery},
  journal = {Cell Stem Cell},
  year = {2023},
  volume = {30},
  number = {6},
  pages = {766--780.e9},
  doi = {10.1016/j.stem.2023.04.017}
}
Kostenlos starten →